Crystalline forms
AssigneeSanofi
InventorsKenneth J. BORDEAU, Beverly C. LANGEVIN, II, George Everett LEE, Patricia LOGUE, Elizabeth SECORD, Daniel SHERER
Life of this patent
Estimating the term…
Abstract
The disclosure relates to crystalline forms of 2-[4-(7-ethyl-5H-pyrrolo[2,3-b]pyrazin-6-yl)-phenyl]-propan-2-ol, characterized by physico-chemical data described herein.
Claims24
A crystalline form of Compound I:
- which is crystalline Form A.
A crystalline form of Compound I
- which is crystalline Form B.
A crystalline form of Compound I
- which is Form C.
A pharmaceutical composition comprising a compound selected from the group consisting of crystalline Form A, Form B and Form C of Compound I:
- together with at least one pharmaceutically acceptable carrier or excipient.
A method of treating a condition in a patient selected from joint inflammation, rheumatoid arthritis, a tumor, and mantle cell lymphoma, comprising administering to a patient in need thereof an effective amount of a a compound selected from the group consisting of crystalline Form A, Form B and Form C of Compound I:
A method of inhibiting angiogenesis in a patient, comprising administering to a patient in need thereof an effective amount of a compound selected from the group consisting of crystalline Form A, Form B and Form C of Compound I:
Dependencies are inferred from the claim text.